This technology focuses on using β-resorcylic acid (β-RA) to cause a selective reduction of white adipose tissue without affecting skeletal muscle mass. This effect favors its use in overweight or obesity treatment, and these factors may be associated with metabolic syndrome or hepatic steatosis.
Overweight and obesity are defined as an abnormal or excessive accumulation of white adipose tissue (WAT) that can be detrimental to health. Consequently, both factors are associated with an increased risk of developing some non-communicable diseases (type II diabetes, metabolic syndrome, cardiovascular diseases, some types of cancer and musculoskeletal disorders, among others).
Although the main strategies used to contain them can trigger a reduction in body weight, it is not possible to ensure in particular cases that this loss links to a reduction only in WAT. On the other hand, the drugs commonly used against type II diabetes, metabolic syndrome or obesity generate very different results among the population and, in some cases, can cause harmful side effects, such as a loss of muscle mass. This fact raises the need for other options that reduce this fat tissue without losing muscle mass or other side effects.
In this sense, the administration of β-resorcylic acid is proposed to prevent the accumulation of WAT or to reduce its content, preserving the content of skeletal muscle mass at the same time. The technology bases on a novel mechanism of action in which β-RA exerts its effect, affecting the hypertrophy and hyperplasia of the WAT.
Its use offers a strategy, both therapeutic and non-therapeutic, aimed at combating and/or preventing overweight and/or obesity, in addition to other associated conditions (accumulation of lipid drops in the liver, hepatic steatosis, etc.). Likewise, a pharmaceutical composition and a nutraceutical composition are presented, which comprise the compound in question, and they are useful for the prevention and/or treatment of these factors and other diseases linked to their development.
ADVANTAGES AND BENEFITS
• Reduction of WAT without affecting the content of muscle mass. The reduction or prevention of accumulation of BAT occurs without altering the skeletal muscle mass content.
• Effect on being overweight and/or obese. The use of the compound raises a strategy (therapeutic and non-therapeutic) aimed to prevent overweight and/or obesity and, also, to treat these factors and other related diseases.
• Preventive effect on hepatic steatosis and appearance of characteristics of non-alcoholic fatty liver.
• Effective agent throughout the population. The effect is exerted regardless of the nutritional condition of the individual.
• Low cost of raw material. Β-resorcylic acid is a natural compound present in various plants, the production of which is inexpensive.
• Production of pharmaceutical and nutraceutical compositions. With β-resorcylic acid in its content, they allow its application for therapeutic and non-therapeutic use, respectively.
Current development status
Laboratory prototypes
Applications
Obesity and overweight treatment.
Obesity and overweight prevention.
White adipose tissue reduction.
Prevention of non-alcoholic hepatic steatosis.
Desired business relationship
Patent licensing
Granada University is one of the most important universities of Spain. The main goal is to transfer technology that our research groups, more than 500, are developing to the industries and companies which are able to take profit from them. It is a general University so Research and Development are offered in different fields like Health Science and Technology, Physics, Chemistry and Mathematics, Environment and Natural Resources, Biotechnology, Information and Communication Technologies, Social, Economic and Legal Sciences....
We hope you find technologies of your interest which will allow us working together in the near future.
Create your free account to connect with Universidad de Granada and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Universidad de Granada
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
![Salts of pyridazino[2,3-a]pyrrolo[2,1-c]quinoxaline for the treatment of leishmania infections and diseases that involve the protein tyrosine phosphatise 1B (metabolic syndrome, diabetes and obesity)](https://static0.innoget.com/uploads/thumb/wide//uploads//3df023970d7a042a76c022ad05180fd34bba60d6.jpg)
